Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by the company's general manager, Mr. Ai Lin, who has reduced his holdings in the company by 1,472,113 shares, representing 0.9690% of the total share capital [1][2]. Group 1: Share Reduction Details - Mr. Ai Lin executed the share reduction through centralized bidding, with an average reduction price of 21.7325 CNY per share [1]. - The total number of shares reduced was 1,472,113, with a price range between 21.3500 CNY and 22.2000 CNY per share [1][2]. - Prior to the reduction, Mr. Ai Lin held 6,014,252 shares, which accounted for 3.9587% of the total share capital [2]. Group 2: Post-Reduction Holdings - After the reduction, Mr. Ai Lin's remaining shares total 4,542,139, which is 2.9897% of the total share capital [2]. - The shares reduced were from the unrestricted category, leaving Mr. Ai Lin with only restricted shares [2]. Group 3: Compliance and Commitments - The share reduction plan was in compliance with relevant laws and regulations, including the Securities Law of the People's Republic of China [2][3]. - Mr. Ai Lin has adhered to his commitments regarding share transfers, including a lock-up period and conditions for future reductions [3][4]. - The reduction will not affect the company's control structure or governance [5].
海森药业: 关于公司董事、高级管理人员减持计划实施完成的公告